黑色素瘤前哨淋巴结活检分期的替代方案与需求减少
综述探讨黑色素瘤中前哨淋巴结活检(SLNB)分期的当前角色与未来趋势。SLNB虽未改善生存但提供最佳分期,辅助免疫检查点抑制(ICI)和靶向治疗(TT)正转向II期患者。作者认为SLNB目前仍有作用,但独立于SLNB状态的治疗选择及经验证的生物标志物(如基因表达谱、免疫组化特征、ctDNA液体活检)将减少其需求,未来十年内可能不再使用。
要点
- SLNB和完成性淋巴结清扫(CLND)均未改善生存,但SLNB分期优于Breslow厚度和溃疡。
- 辅助ICI和TT试验均基于SLN状态和SLN肿瘤负荷,但辅助治疗正转向II期黑色素瘤。
- IIB/C期患者若无论SLNB结果均接受辅助治疗,可能放弃核素扫描及SLNB相关手术风险。
核心结论
- SLNB分期在当前黑色素瘤中仍有作用,但预计未来十年内随着独立于SLNB状态的治疗选择及经验证的预测风险生物标志物的出现,其需求将减少至不再使用。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- SLNB和CLND均未改善生存,但SLNB分期提供了优于Breslow厚度和溃疡的最佳分期。
- 迄今所有现代辅助系统治疗(ICI或TT)试验均使用SLN状态和SLN肿瘤负荷。
- 辅助ICI和TT正转向II期黑色素瘤。
- 对于IIB/C期患者,若无论SLNB结果均接受辅助治疗,似乎可能放弃核素扫描及SLNB相关手术干预和并发症风险。
- 对于I/IIA期,仍需要SLNB检测可能从辅助治疗获益的高危患者。
关键数值与推荐
- SLN状态和SLN肿瘤负荷可能有助于讨论需治疗人数以进行风险/获益讨论。
- 新兴生物标志物包括基因表达谱(GEP)、免疫组化特征和ctDNA液体活检。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sentinel lymph node biopsy (SLNB) has been introduced in the 1990s to identify patients who might benefit from completion lymph node dissection. Neither SLNB nor CLND improved survival, but SLNB staging did provide the best staging, above Breslow thickness and ulceration. The SLN status and SLN tumour burden were used in all trials until date looking at modern adjuvant systemic therapy with immune checkpoint inhibition (ICI) or targeted therapies (TT). Adjuvant ICI and TT are shifting towards stage II melanoma. The question is whether there is still role for SLNB in melanoma, in this day and age, and if so, how does the future look for SLNB staging? The SLN status and SLN tumour burden might be useful for a consultation to discuss the number needed to treat in a risk/benefit discussion. For stage IIB/C patients, it seems likely, however, that patients will forego a nuclear scan followed by the risk of surgical intervention and morbidity associated with SLNB if they opt to receive adjuvant therapy regardless of the SLNB result. For stage I/IIA, it is still required to detect high-risk patients who might benefit from adjuvant therapy. However, biomarkers are emerging, such as gene expression profilers (GEP), immunohistological signatures and liquid biopsies with ctDNA. There still is a role for SLNB staging in melanoma today, but we expect that the availability of therapeutic option independent of SLNB status as well as emergence of validated biomarkers to predict risk will reduce the need for SLNB staging in the upcoming decade to the point it will no longer be used.
引用
- van Akkooi ACJ, Schadendorf D, Eggermont AMM, et al. Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. Eur J Cancer. 2022. PMID: 36681612. doi:10.1016/j.ejca.2022.12.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。